Search results
Showing 1 to 9 of 9 results for fremanezumab
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 764.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
145,000 people in England to have further treatment choice for preventing migraine attacks
NICE has for the first time recommended an oral treatment for preventing migraines.